anti-CD20 mAb (Novartis Pharma AG)

N/A

Report date: 2025/03/14 16:25:02

Base Information

Drug Nameanti-CD20 mAb (Novartis Pharma AG)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionB-lymphocyte antigen CD20 inhibitors
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New ZealandSwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Institutes For Biomedical Research Inc
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Institutes For Biomedical Research IncLa Trobe UniversityThe University Of Queensland
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A